The Cajal Institute in Madrid
Research in neuroscience has a longstanding tradition in Spain mostly inspired by Nobel Prize winner Santiago Ramón y Cajal and his disciples, for whom the “Instituto Cajal” (IC) was initially conceived in 1934. Five years later the Spanish Government created the National Research Council under the name of Consejo Superior de Investigaciones Cientificas (CSIC) and the IC became one of the first centers of this new Institution. The IC is one of the two CSIC centers fully devoted to research in Neuroscience. The Institute moved to its present location in downtown Madrid in a building of 4,500 m2 in 1989. Currently the IC houses 25 independent research teams and around 200 staff, with operating costs close to 9 K€/year.
From its inception the Cajal Institute has contributed to the advance in Neuroscience and has hosted and formed many of the neuroscientists working now in the different Spanish research and academic centers. Along almost one century of life, the Institute has become a center of worldwide reputation, building on the important contributions of its founder to the present day. Current staff of the Institute has been selected under a tight competitive system according to the high standards of the CSIC. Presently, the institute is organized in two departments: Functional and Systems Neurobiology, and Cellular, Molecular and Developmental Neurobiology, which intend to agglutinate research in all major areas of neuroscience. The focus of the IC research can be comprised in five major lines:
– Mechanisms of neural specification
– The neuro-vascular unit
– Processing of neural signals (a new line of work in neuro-prosthetics and bioengineering is being planned to be incorporated in the near future to reinforce this section)
– Neuroprotection and regeneration
– Systemic modulators of brain function
Contact information:
Cajal Institute (CSIC)
Avenida Doctor Arce 37
28002 Madrid.
Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is…
Having forged a solid position in clinical research in 2020 and 2021 when it became the fourth nation in the world and the first in Europe for studies conducted around…
The European Union’s just-released and first essential medicines list is the latest in a series of measures designed to limit the bloc’s reliance on countries outside its borders and avoid…
The COVID-19 pandemic and subsequent shortages of essential medicines and APIs laid bare Europe’s reliance on suppliers outside its borders. To combat this issue and ensure that Europe is better…
A roundup of the latest news from Spanish pharma, including Almirall’s licensing deal with EpimAb Biotherapeutics; the opening of Insud Pharma’s oligonucleotides centre in India, and Esteve Química’s new FDA-cleared…
Spanish mid-cap Esteve is selling a 26 percent stake in the company to German private investment firm Lubea, a move it says will supply the necessary funds to further pursue…
The latest news from Spanish pharmaceuticals and healthcare, including national champion Esteve’s decision to sell of a quarter of its stock to German private investment firm Lubea; news of pharma’s…
A roundup of the latest news from Spanish pharma, including Almirall’s earnings forecast for 2023; stock price rise and layoffs at Grifols; PharmaMar’s first European approval for its lurbinectedin treatment…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
What major regulatory trends are emerging in Europe and in Spain? As one of the founding partners of a law firm focused uniquely on the life sciences industry, Faus &…
Faus & Moliner Abogados is a Spanish law firm that has been specializing in pharma and life sciences law since 1997. Founding partner Jordi Faus explains how having a comprehensive…
Over the course of 2022, PharmaBoardroom spoke to over 50 leading stakeholders in the Spanish healthcare and life sciences, from top Spanish scientists to regional ministers of health, multinational affiliate…
See our Cookie Privacy Policy Here
